Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8783820 | 0.82 | RIPK1 (0.33) | CYP2C19P2RX7KDM1AMAOAMAOB | |
| SCHEMBL18889652 | 0.80 | MAOB (0.39) | CYP2C19CHRNA7KDM1AMAOAMAOB | |
| SCHEMBL9249456 | 0.76 | RIPK1 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7068812 | 0.72 | NOS1 (0.40) | CYP2C19SLC18A3SIGMAR1KDM1AMAOA | |
| SCHEMBL11813240 | 0.71 | — | — | |
| SCHEMBL15532637 | 0.67 | MAOB (0.41) | CYP2C19KDM1AMAOAMAOBSLC6A2 | |
| SCHEMBL7609774 | 0.67 | KDM1A (0.46) | KDM1AMAOBMEN1KMT2ASLC6A2 | |
| SCHEMBL3389545 | 0.65 | NOS1 (0.46) | CYP2C19SLC18A3KDM1AMAOAMAOB | |
| SCHEMBL20080246 | 0.64 | MAOB (0.40) | CHRNB4CHRNA3P2RX7MAOAMAOB | |
| SCHEMBL11711361 | 0.64 | P2RX7 (0.36) | CYP2C19CHRNA7P2RX7KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149469-B2 | Pharmaceutical composition and a process thereof | INDUS BIOTECH PVT. LTD. (IN) | 2015-10-06 | — | — | US | disclosed |
| US-8702939-B2 | Electrotaxis methods and devices | MCMASTER UNIVERSITY (CA) | 2014-04-22 | — | — | US | disclosed |
| US-8633229-B2 | Pharmaceutical composition having dopaminergic activity | INDUS BIOTECH PVT. LTD. (IN) | 2014-01-21 | — | — | US | disclosed |
| EP-2114393-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING TRIGONELLINE AND 4-HYDROXYISOLEUCINE AND A PROCESS THEREOF | INDUS BIOTECH PRIVATE LTD (IN) | 2013-04-17 | — | — | EP | disclosed |
| US-8241648-B2 | Synthetically modified fullerene molecules; ellipsoid with an equatorial band and two opposing poles; adduct at poles, hydrophobic chemical moiety capable of anchoring the fullerene on or in a lipid membrane; ointment, cream, lotion, moisturized patch or moisture-free patch, shampoo, gel, rinse | LUNA INNOVATIONS INCORPORATED (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120061240-A1 | ELECTROTAXIS METHODS AND DEVICES | MCMASTER UNIVERSITY (CA) | 2012-03-15 | — | — | US | disclosed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
| EP-2101768-A2 | USE OF NEUROPROTECTIVE COMPOUNDS FOR OBTAINING DRUGS FOR TREATING NEURODEGENERATIVE DISEASES | Les Laboratoires Servier (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008109031-A2 | LIPOSOME CARRIERS FOR IN VIVO DELIVERY OF FULLERENES | LUNA INNOVATIONS INCORPORATED (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109032-A2 | AMPHIPHILIC OR LIPOPHILIC POLAR FUNCTIONALIZED FULLERENES AND THEIR USES | LUNA INNOVATIONS INCORPORATED (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221173-A1 | PHARMACEUTICAL COMPOSITION AND A PROCESS THEREOF | INDUS BIOTECH PVT. LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| US-20080213352-A1 | Liposome carriers for in vivo delivery of fullerenes | LUNA INNOVATIONS INCORPORATED (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080213324-A1 | Amphiphilic or lipophilic polar functionalized fullerenes and their uses | LUNA INNOVATIONS INCORPORATED (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008099083-A2 | USE OF NEUROPROTECTIVE COMPOUNDS FOR OBTAINING DRUGS FOR TREATING NEURODEGENERATIVE DISEASES | LES LABORATOIRES SERVIER (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | NLN, GAP43, SNCA | CYP2C19 4858/4885SLC18A3 64/4885CHRNB2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.